References
- Wallace DC (2012) Mitochondria and cancer. Nat Rev Cancer 12, 685 https://doi.org/10.1038/nrc3365
- Green DR, Galluzzi L and Kroemer G (2011) Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 333, 1109-1112 https://doi.org/10.1126/science.1201940
- Chen H and Chan DC (2009) Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 18, R169-R176 https://doi.org/10.1093/hmg/ddp326
- Pfanner N, Warscheid B and Wiedemann N (2019) Mitochondrial proteins: from biogenesis to functional networks. Nat Rev Mol Cell Biol 20, 267-284 https://doi.org/10.1038/s41580-018-0092-0
- Braestrup C, Albrechtsen R and Squires RF (1977) High densities of benzodiazepine receptors in human cortical areas. Nature 269, 702-704 https://doi.org/10.1038/269702a0
- Papadopoulos V (1998) Structure and function of the peripheral-type benzodiazepine receptor in steroidogenic cells. Proc Soc Exp Biol Med 217, 130-142 https://doi.org/10.3181/00379727-217-44215
- Azarashvili T, Krestinina O, Yurkov I, Evtodienko Y and Reiser G (2005) High-affinity peripheral benzodiazepine receptor ligand, PK11195, regulates protein phosphorylation in rat brain mitochondria under control of Ca2+. J Neurochem 94, 1054-1062 https://doi.org/10.1111/j.1471-4159.2005.03260.x
- Hirsch JD, Beyer CF, Malkowitz L, Beer B and Blume AJ (1989) Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. Mol Pharm 35, 157-163
- Hirsch T, Decaudin D, Susin SA et al (1998) PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp Cell Res 241, 426-434 https://doi.org/10.1006/excr.1998.4084
- Lee D, Kang S, Lee R et al (2004) Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells. J Cell Physiol 198, 91-99 https://doi.org/10.1002/jcp.10391
- Kim T and Pae AN (2016) Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: A patent review (2010-2015; part 1). Expert Opin Ther Pat 26, 1325-1351 https://doi.org/10.1080/13543776.2016.1230606
- Fan J, Lindemann P, GJ Feuilloley M and Papadopoulos V (2012) Structural and functional evolution of the translocator protein (18 kDa). Curr Mol Med 12, 369-386 https://doi.org/10.2174/1566524011207040369
- Yeliseev AA, Krueger KE and Kaplan S (1997) A mammalian mitochondrial drug receptor functions as a bacterial "oxygen" sensor. Proc Natl Acad Sci U S A 94, 5101-5106 https://doi.org/10.1073/pnas.94.10.5101
- Chapalain A, Chevalier S, Orange N, Murillo L, Papadopoulos V and Feuilloley MG (2009) Bacterial ortholog of mammalian translocator protein (TSPO) with virulence regulating activity. PLoS One 4, e6096 https://doi.org/10.1371/journal.pone.0006096
- Riond J, Leplatois P, Laurent P et al (1991) Expression and pharmacological characterization of the human peripheraltype benzodiazepine receptor in yeast. Eur J Pharmacol 208, 307-312 https://doi.org/10.1016/0922-4106(91)90076-T
- Fan J, Rone MB and Papadopoulos V (2009) Translocator protein 2 is involved in cholesterol redistribution during erythropoiesis. J Biol Chem 284, 30484-30497 https://doi.org/10.1074/jbc.M109.029876
- Li F, Liu J, Zheng Y, Garavito RM and Ferguson-Miller S (2015) Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism. Science 347, 555-558 https://doi.org/10.1126/science.1260590
- Jaremko L, Jaremko M, Giller K, Becker S and Zweckstetter M (2014) Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 343, 1363-1366 https://doi.org/10.1126/science.1248725
- Guo Y, Kalathur RC, Liu Q et al (2015) Structure and activity of tryptophan-rich TSPO proteins. Science 347, 551-555 https://doi.org/10.1126/science.aaa1534
- Veenman L, Vainshtein A, Yasin N, Azrad M and Gavish M (2016) Tetrapyrroles as endogenous TSPO ligands in eukaryotes and prokaryotes: Comparisons with synthetic ligands. Int J Mol Sci 17, 880 https://doi.org/10.3390/ijms17060880
- Owen DR, Yeo AJ, Gunn RN et al (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32, 1-5 https://doi.org/10.1038/jcbfm.2011.147
- Toor JS and Sikka SC (2017) Developmental and Reproductive Disorders-Role of Endocrine Disruptors in Testicular Toxicity; in Rep Dev Toxicol 1111-1121, Elsevier,
- Papadopoulos V, Mukhin A, Costa E and Krueger K (1990) The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J Bioll Chem 265, 3772-3779 https://doi.org/10.1016/S0021-9258(19)39661-9
- Chung J-Y, Chen H, Midzak A, Burnett A, Papadopoulos V and Zirkin BR (2013) Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells. Endocrinology 154, 2156-2165 https://doi.org/10.1210/en.2012-2226
- Papadopoulos V, Amri H, Li H, Boujrad N, Vidic B and Garnier M (1997) Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J Biol Chem 272, 32129-32135 https://doi.org/10.1074/jbc.272.51.32129
- Hauet T, Yao ZX, Bose HS et al (2005) Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into leydig cell mitochondria. Mol Endocrinol 19, 540-554 https://doi.org/10.1210/me.2004-0307
- McEnery MW, Snowman AM, Trifiletti RR and Snyder SH (1992) Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci U S A 89, 3170-3174 https://doi.org/10.1073/pnas.89.8.3170
- Buki A, Okonkwo DO, Wang KK and Povlishock JT (2000) Cytochrome c release and caspase activation in traumatic axonal injury. J Neurosci 20, 2825-2834 https://doi.org/10.1523/jneurosci.20-08-02825.2000
- Lemasters JJ, Theruvath TP, Zhong Z and Nieminen A-L (2009) Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta Bioenerg 1787, 1395-1401 https://doi.org/10.1016/j.bbabio.2009.06.009
- Azarashvili T, Krestinina O, Baburina Y et al (2015) Combined effect of G3139 and TSPO ligands on Ca2+-induced permeability transition in rat brain mitochondria. Arch Biochem Biophys 587, 70-77 https://doi.org/10.1016/j.abb.2015.10.012
- Shoshan-Barmatz V, Pittala S and Mizrachi D (2019) VDAC1 and the TSPO: Expression, Interactions, and Associated Functions in Health and Disease States. Int J Mol Sci 20, 3348 https://doi.org/10.3390/ijms20133348
- Selvaraj V and Stocco DM (2015) The changing landscape in translocator protein (TSPO) function. Trends Endocrinol Metab 26, 341-348 https://doi.org/10.1016/j.tem.2015.02.007
- Kim S, Kim N, Park S et al (2019) Tanycytic TSPO inhibition induces lipophagy to regulate lipid metabolism and improve energy balance. Autophagy [Epub ahead of print]
- Lee JW, Nam H and Yu SW (2016) Systematic analysis of translocator protein 18 kDa (TSPO) ligands on toll-like receptors-mediated pro-inflammatory responses in microglia and astrocytes. Exp Neurobiol 25, 262-268 https://doi.org/10.5607/en.2016.25.5.262
- Notter T, Coughlin JM, Sawa A and Meyer U (2018) Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry. Mol Psychiatry 23, 36 https://doi.org/10.1038/mp.2017.232
- Christensen A and Pike CJ (2018) TSPO ligand PK11195 improves Alzheimer-related outcomes in aged female 3xTg-AD mice. Neurosci Lett 683, 7-12 https://doi.org/10.1016/j.neulet.2018.06.029
- Gong J, Szego EM, Leonov A et al (2019) Translocator protein ligand protects against neurodegeneration in the MPTP mouse model of Parkinsonism. J Neurosci 39, 3752-3769 https://doi.org/10.1523/JNEUROSCI.2070-18.2019
- Daugherty DJ, Selvaraj V, Chechneva OV, Liu XB, Pleasure DE and Deng W (2013) A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med 5, 891-903 https://doi.org/10.1002/emmm.201202124
- Verleye M, Akwa Y, Liere P et al (2005) The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behar 82, 712-720 https://doi.org/10.1016/j.pbb.2005.11.013
- Okuyama S, Chaki S, Yoshikawa R et al (1999) Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci 64, 1455-1464 https://doi.org/10.1016/S0024-3205(99)00079-X
- Wang D-s, Tian Z, Guo Y-y et al (2015) Anxiolytic-like effects of translocator protein (TSPO) ligand ZBD-2 in an animal model of chronic Pain. Mol Pain 11, 16 https://doi.org/10.1186/s12990-015-0013-6
- Da Pozzo E, Giacomelli C, Barresi E et al (2015) Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Biochem Soc Trans 43, 559-565 https://doi.org/10.1042/BST20150028
- Kim EJ and Yu SW (2015) Translocator protein 18 kDa (TSPO): old dogma, new mice, new structure, and new questions for neuroprotection. Neural Regen Res 10, 878 https://doi.org/10.4103/1673-5374.158338
- Kupa LdVK, Drewes CC, Barioni ED, Neves CL, Sampaio SC and Farsky SH (2017) Role of Translocator 18 KDa Ligands in the Activation of Leukotriene B4 Activated G-Protein Coupled Receptor and Toll Like Receptor-4 Pathways in Neutrophils. Front Pharmacol 8, 766 https://doi.org/10.3389/fphar.2017.00766
- Lee JW, Kim LE, Shim HJ, Kim EK, Hwang WC and Yu S-W (2016) A translocator protein 18 kDa ligand, Ro5-4864, inhibits ATP-induced NLRP3 inflammasome activation. Biochem Biophys Res Comm 474, 587-593 https://doi.org/10.1016/j.bbrc.2016.04.080
- Wang W, Zhang L, Zhang X et al (2016) Lentiviralmediated overexpression of the 18 kDa translocator protein (TSPO) in the hippocampal dentate gyrus ameliorates LPS-induced cognitive impairment in mice. Front Pharmacol 7, 384
- Bae KR, Shim HJ, Balu D, Kim SR and Yu SW (2014) Translocator protein 18 kDa negatively regulates inflammation in microglia. J Neuroimmune Pharmacol 9, 424-437 https://doi.org/10.1007/s11481-014-9540-6
- Wang M, Wang X, Zhao L et al (2014) Macrogliamicroglia interactions via TSPO signaling regulates microglial activation in the mouse retina. J Neurosci 34, 3793-3806 https://doi.org/10.1523/JNEUROSCI.3153-13.2014
- Deczkowska A and Schwartz M (2018) Targeting neuro-immune communication in neurodegeneration: Challenges and opportunities. J Exp Med 215, 2702-2704 https://doi.org/10.1084/jem.20181737
- Schwartz M (2017) Can immunotherapy treat neurodegeneration? Science 357, 254-255 https://doi.org/10.1126/science.aai8231
- Notter T, Coughlin JM, Gschwind T et al (2018) Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Mol Psychiatry 23, 323 https://doi.org/10.1038/mp.2016.248
- Owen DR, Narayan N, Wells L et al (2017) Proinflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. J Cereb Blood Flow Metab 37, 2679-2690 https://doi.org/10.1177/0271678X17710182
- Daugherty DJ, Chechneva O, Mayrhofer F and Deng W (2016) The hGFAP-driven conditional TSPO knockout is protective in a mouse model of multiple sclerosis. Sci Rep 6, 22556 https://doi.org/10.1038/srep22556
- Milenkovic VM, Slim D, Bader S et al (2019) CRISPR-Cas9 Mediated TSPO Gene Knockout alters Respiration and Cellular Metabolism in Human Primary Microglia Cells. Int J Mol Sci 20, 3359 https://doi.org/10.3390/ijms20133359
- Alam MM, Lee J and Lee S-Y (2017) Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurological diseases. Nucl Med Mol Imaging 51, 283-296 https://doi.org/10.1007/s13139-017-0475-8
- Debruyne J, Versijpt J, Van Laere K et al (2003) PET visualization of microglia in multiple sclerosis patients using [11C] PK11195. Eur J Neurol 10, 257-264 https://doi.org/10.1046/j.1468-1331.2003.00571.x
- Cagnin A, Brooks DJ, Kennedy AM et al (2001) In-vivo measurement of activated microglia in dementia. The Lancet 358, 461-467 https://doi.org/10.1016/S0140-6736(01)05625-2
- Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21, 404-412 https://doi.org/10.1016/j.nbd.2005.08.002
- Turner M, Cagnin A, Turkheimer F et al (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15, 601-609 https://doi.org/10.1016/j.nbd.2003.12.012
- Chauveau F, Boutin H, Van Camp N et al (2011) In vivo imaging of neuroinflammation in the rodent brain with [11 C] SSR180575, a novel indoleacetamide radioligand of the translocator protein (18 kDa). Eur J Nucl Med Mol Imaging 38, 509-514 https://doi.org/10.1007/s00259-010-1628-5
- Li L, Chen T, Stanton JD, Sueyoshi T, Negishi M and Wang H (2008) The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol Pharmacol 74, 443-453 https://doi.org/10.1124/mol.108.046656
- Bordet T, Buisson B, Michaud M et al (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322, 709-720 https://doi.org/10.1124/jpet.107.123000
- Schaller S, Paradis S, Ngoh GA et al (2010) TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther 333, 696-706 https://doi.org/10.1124/jpet.110.167486
- Nguyen N, Fakra E, Pradel V et al (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21, 139-149 https://doi.org/10.1002/hup.757
- do Rego JL, Vaudry D and Vaudry H (2015) The nonbenzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS One 10, e0120473 https://doi.org/10.1371/journal.pone.0120473
- Rupprecht R, Rammes G, Eser D et al (2009) Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490-493 https://doi.org/10.1126/science.1175055
- Biswas L, Farhan F, Reilly J, Bartholomew C and Shu X (2018) TSPO Ligands Promote Cholesterol Efflux and Suppress Oxidative Stress and Inflammation in Choroidal Endothelial Cells. Int J Mol Sci 19, 3740 https://doi.org/10.3390/ijms19123740
- Tu LN, Morohaku K, Manna PR et al (2014) Peripheral benzodiazepine receptor/translocator protein global knockout mice are viable with no effects on steroid hormone biosynthesis. J Biol Chem 289, 27444-27454 https://doi.org/10.1074/jbc.M114.578286
- Morohaku K, Pelton SH, Daugherty DJ, Butler WR, Deng W and Selvaraj V (2014) Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 155, 89-97 https://doi.org/10.1210/en.2013-1556
- Sileikyte J, Blachly-Dyson E, Sewell R et al (2014) Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (Translocator Protein of 18 kDa (TSPO)). J Biol Chem 289, 13769-13781 https://doi.org/10.1074/jbc.M114.549634
- Zhao AH, Tu LN, Mukai C et al (2016) Mitochondrial translocator protein (TSPO) function is not essential for heme biosynthesis. J Biol Chem 291, 1591-1603 https://doi.org/10.1074/jbc.M115.686360
- Tu LN, Zhao AH, Stocco DM and Selvaraj V (2015) PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO). Endocrinology 156, 1033-1039 https://doi.org/10.1210/en.2014-1707
- Hatty CR, Le Brun AP, Lake V et al (2014) Investigating the interactions of the 18 kDa translocator protein and its ligand PK11195 in planar lipid bilayers. Biochim Biophys Acta Biomembr 1838, 1019-1030 https://doi.org/10.1016/j.bbamem.2013.12.013
- Bader S, Wolf L, Milenkovic VM et al (2019) Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells. Psychoneuroendocrinology 106, 65-76 https://doi.org/10.1016/j.psyneuen.2019.03.029